p55^gag pdna vaccine
Vaccineexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2017 (NCT03181789)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- p55^gag pdna vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03560258 | Phase 1/Phase 2 (Phase 2) | Nov 17, 2018 | National Institute of Allergy and Infectious Diseases (NIAID), Temple University |
| NCT03181789 | Phase 1 | Jul 1, 2017 | City of San Francisco, National Institute of Allergy and Infectious Diseases (NIAID), Vanderbilt University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 2 | 2 | 2 | 2017 |
| City of San Francisco | Government | 1 | 0 | 1 | 2017 |
| Temple University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Vanderbilt University | Academic/Hospital | 1 | 0 | 1 | 2017 |
4 organizations
Page 1 / 1